[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
Oct 2011

Oral Propranolol for Exudative Retinal Detachment in Diffuse Choroidal Hemangioma

Author Affiliations

Author Affiliations: Retina and Vitreous Service, Clínica Oftalmológica Centro Caracas, Caracas, Venezuela. Dr Arevalo is now with the Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, and the Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.

Arch Ophthalmol. 2011;129(10):1373-1375. doi:10.1001/archophthalmol.2011.294

The main abnormality of the uveal tract in patients with Sturge-Weber syndrome is diffuse choroidal hemangioma (DCH). Diffuse choroidal hemangioma can lead to a total retinal detachment and secondary neovascular glaucoma. Radiotherapy and photodynamic therapy are currently the preferred methods of treatment. Low-dose lens-sparing radiotherapy or proton beam irradiation can induce tumor regression and resolution of subretinal fluid.1 Short-term treatment success using photodynamic therapy has also been reported.2

The use of oral propranolol hydrochloride has been described for infantile orbital3 and periorbital hemangioma. Recently, Léauté-Labrèze et al3 observed that systemic propranolol could inhibit the growth of infantile hemangioma (IH) lesions in children. The response of IH to propranolol catapulted the use of this treatment to first-line status among physicians managing this disease.3-6

×